Pirbuterol (BioDeep_00000002069)

 

Secondary id: BioDeep_00001868118

human metabolite blood metabolite


代谢物信息卡片


2-Hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-tert-butylamino ethyl)pyridine, dihydrochloride

化学式: C12H20N2O3 (240.1474)
中文名称:
谱图信息: 最多检出来源 Homo sapiens(blood) 69.19%

分子结构信息

SMILES: CC(C)(C)NCC(C1=NC(=C(C=C1)O)CO)O
InChI: InChI=1S/C12H20N2O3/c1-12(2,3)13-6-11(17)8-4-5-10(16)9(7-15)14-8/h4-5,11,13,15-17H,6-7H2,1-3H3

描述信息

Pirbuterol is a beta-2 adrenergic bronchodilator. In vitro studies and in vivo pharmacologic studies have demonstrated that pirbuterol has a preferential effect on beta-2 Adrenergic receptors compared with isoproterenol. While it is recognized that beta-2 adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta-2 receptors in the human heart, existing in a concentration between 10-50\\%. The precise function of these receptors has not been established. The pharmacologic effects of beta adrenergic agonist drugs, including pirbuterol, are at least in proof attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (AlP) to cyclic-3† ,5†-adenosine monophosphate (c-AMP). Increased c-AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.
R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03C - Adrenergics for systemic use > R03CC - Selective beta-2-adrenoreceptor agonists
R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03A - Adrenergics, inhalants > R03AC - Selective beta-2-adrenoreceptor agonists
D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents
C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist
D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists
D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents
D020011 - Protective Agents > D002316 - Cardiotonic Agents
D002317 - Cardiovascular Agents

同义名列表

11 个代谢物同义名

2-Hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-tert-butylamino ethyl)pyridine, dihydrochloride; 6-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)pyridin-3-ol; 3m Brand OF pirbuterol acetate; Pirbuterol dihydrochloride; Pirbuterol acetate salt; Pirbuterol Acetate; Pirbuterol sulfate; PIRBUTEROL; Pyrbuterol; Maxair; Pirbuterol



数据库引用编号

18 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表
Cytoplasm 7 ADRA1A, AIMP2, ALOX5, MAPK8, RAF1, STAT3, TH
Peripheral membrane protein 1 ALOX5
Endosome membrane 1 ADRB2
Nucleus 7 ADRA1A, ADRB2, AIMP2, MAPK8, RAF1, STAT3, TH
cytosol 9 ADRA1A, AIMP2, ALOX5, COMT, LIPE, MAPK8, RAF1, STAT3, TH
dendrite 2 COMT, TH
nucleoplasm 4 ADRA1A, ALOX5, MAPK8, STAT3
RNA polymerase II transcription regulator complex 1 STAT3
Cell membrane 8 ADRA1A, ADRB1, ADRB2, ADRB3, COMT, CYSLTR2, LIPE, RAF1
Cell projection, axon 1 TH
Multi-pass membrane protein 5 ADRA1A, ADRB1, ADRB2, ADRB3, CYSLTR2
Synapse 2 COMT, MAPK8
Golgi apparatus 2 ADRB2, RAF1
Golgi membrane 1 INS
smooth endoplasmic reticulum 1 TH
synaptic vesicle 1 TH
Cytoplasm, cytosol 3 AIMP2, ALOX5, LIPE
Lysosome 1 ADRB2
endosome 1 ADRB2
plasma membrane 9 ADRA1A, ADRB1, ADRB2, ADRB3, COMT, CYSLTR2, EDNRA, RAF1, STAT3
terminal bouton 1 TH
Membrane 4 ADRB2, AIMP2, COMT, LIPE
apical plasma membrane 1 ADRB2
axon 3 COMT, MAPK8, TH
caveola 2 ADRA1A, LIPE
extracellular exosome 1 COMT
extracellular space 3 ALOX5, GH1, INS
perinuclear region of cytoplasm 2 ALOX5, TH
Schaffer collateral - CA1 synapse 1 ADRB1
mitochondrion 2 RAF1, TH
intracellular membrane-bounded organelle 2 ADRA1A, COMT
Secreted 3 GH1, INS, MDK
extracellular region 4 ALOX5, GH1, INS, MDK
cytoplasmic side of plasma membrane 1 TH
mitochondrial outer membrane 1 RAF1
Extracellular side 1 COMT
transcription regulator complex 1 STAT3
Nucleus membrane 2 ADRA1A, ALOX5
nuclear membrane 2 ADRA1A, ALOX5
perikaryon 1 TH
cytoplasmic vesicle 1 TH
Melanosome membrane 1 TH
Early endosome 2 ADRB1, ADRB2
Single-pass type II membrane protein 1 COMT
Cytoplasm, perinuclear region 2 ALOX5, TH
receptor complex 2 ADRB2, ADRB3
neuron projection 1 TH
chromatin 1 STAT3
nuclear envelope 1 ALOX5
Nucleus envelope 1 ALOX5
endosome lumen 2 GH1, INS
Lipid droplet 1 LIPE
Membrane, caveola 2 ADRA1A, LIPE
pseudopodium 1 RAF1
ficolin-1-rich granule lumen 1 ALOX5
secretory granule lumen 2 ALOX5, INS
Golgi lumen 1 INS
endoplasmic reticulum lumen 1 INS
nuclear matrix 1 ALOX5
transport vesicle 1 INS
Endoplasmic reticulum-Golgi intermediate compartment membrane 1 INS
neuronal dense core vesicle 2 ADRB1, ADRB2
Nucleus matrix 1 ALOX5
nuclear envelope lumen 1 ALOX5
clathrin-coated endocytic vesicle membrane 1 ADRB2
basal dendrite 1 MAPK8
aminoacyl-tRNA synthetase multienzyme complex 1 AIMP2
growth hormone receptor complex 1 GH1
Cytoplasmic vesicle, secretory vesicle, synaptic vesicle 1 TH
Nucleus intermembrane space 1 ALOX5
[Isoform Soluble]: Cytoplasm 1 COMT
[Isoform Membrane-bound]: Cell membrane 1 COMT


文献列表

  • H Windom, J Grainger, C Burgess, J Crane, N Pearce, R Beasley. A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol. The New Zealand medical journal. 1990 Jun; 103(891):259-61. doi: . [PMID: 1972557]
  • F Stroman, H Herold, I Szelenyi. Influence of various adrenergic compounds on plasma potassium levels in conscious dogs and anaesthetized domestic pigs. Arzneimittel-Forschung. 1989 Dec; 39(12):1562-5. doi: . [PMID: 2576204]
  • R Canepa-Anson, J R Dawson, P Kuan, P A Poole-Wilson, G C Sutton, B Cockrill, S R Reuben. Differences between acute and long-term metabolic and endocrine effects of oral beta-adrenoceptor agonist therapy with pirbuterol for cardiac failure. British journal of clinical pharmacology. 1987 Feb; 23(2):173-81. doi: 10.1111/j.1365-2125.1987.tb03026.x. [PMID: 3828194]
  • V Grassi, S Daniotti, M Schiassi, M Dottorini, C Tantucci. Oral beta 2-selective adrenergic bronchodilators. International journal of clinical pharmacology research. 1986; 6(2):93-103. doi: . [PMID: 2873108]
  • J Brès, A M Clauzel, M C Pistre, H Rachmat, F Bressolle. [Metabolism of beta-adrenergic substances. Therapeutic implications]. Bulletin europeen de physiopathologie respiratoire. 1985 Sep; 21(5):19s-34s. doi: . [PMID: 2865990]
  • S F Vatner, D R Knight, T H Hintze. Norepinephrine-induced beta 1-adrenergic peripheral vasodilation in conscious dogs. The American journal of physiology. 1985 Jul; 249(1 Pt 2):H49-56. doi: 10.1152/ajpheart.1985.249.1.h49. [PMID: 2861749]
  • O A Smiseth. Effects of the beta-adrenergic receptor agonist pirbuterol on cardiac performance during acute ischaemic left ventricular failure in dogs. European journal of pharmacology. 1983 Mar; 87(4):379-86. doi: 10.1016/0014-2999(83)90076-6. [PMID: 6133759]
  • K T Weber, V Andrews, J S Janicki. Cardiotonic agents in the management of chronic cardiac failure. American heart journal. 1982 Apr; 103(4 Pt 2):639-49. doi: 10.1016/0002-8703(82)90469-0. [PMID: 7064806]
  • C V Leier, S Nelson, P Huss, J R Bianchine, A Y Olukotun, C R Taylor, D S Salzburg. Intravenous pirbuterol. Clinical pharmacology and therapeutics. 1982 Jan; 31(1):89-94. doi: 10.1038/clpt.1982.14. [PMID: 7053311]
  • H V Levinsky, C Breckenridge, R Lough, D A Gonci, H M McIlhenny, S Qureshi. Six month inhalation studies of pirbuterol acetate aerosol in the beagle dog and squirrel monkey. Fundamental and applied toxicology : official journal of the Society of Toxicology. 1981 Nov; 1(6):426-31. doi: 10.1016/s0272-0590(81)80022-x. [PMID: 7185594]
  • B Sharma, J Hoback, G S Francis, M Hodges, R W Asinger, J N Cohn, C R Taylor. Pirbuterol: a new oral sympathomimetic amine for the treatment of congestive heart failure. American heart journal. 1981 Sep; 102(3 Pt 2):533-41. doi: 10.1016/0002-8703(81)90741-9. [PMID: 6115572]
  • J R Dawson, R Canepa-Anson, P Kuan, N H Whitaker, J Carnie, C Warnes, S R Reuben, P A Poole-Wilson, G C Sutton. Treatment of chronic heart failure with pirbuterol: acute haemodynamic responses. British medical journal (Clinical research ed.). 1981 May; 282(6274):1423-6. doi: 10.1136/bmj.282.6274.1423. [PMID: 6112039]
  • J W Constantine, H M McIlhenny, P F Moore. Pharmacokinetics and cardiopulmonary effects in dogs of sublingual pirbuterol, a new bronchodilator. The Journal of pharmacology and experimental therapeutics. 1979 Mar; 208(3):371-6. doi: NULL. [PMID: 430357]
  • N K Burki, L Diamond. Long-term oral bronchodilator therapy of asthma with pirbuterol. Clinical pharmacology and therapeutics. 1978 Jul; 24(1):84-9. doi: 10.1002/cpt197824184. [PMID: 657723]
  • F C Falkner, H M McIlhenny. Selected ion monitoring assay for the bronchodilator pirbuterol. Biomedical mass spectrometry. 1976 Oct; 3(5):207-11. doi: 10.1002/bms.1200030503. [PMID: 974234]